These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
156 related items for PubMed ID: 19731037
1. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Aroui S, Brahim S, Hamelin J, De Waard M, Bréard J, Kenani A. Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037 [Abstract] [Full Text] [Related]
2. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Aroui S, Brahim S, De Waard M, Bréard J, Kenani A. Cancer Lett; 2009 Nov 18; 285(1):28-38. PubMed ID: 19523755 [Abstract] [Full Text] [Related]
3. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Mol Cancer Res; 2009 Nov 18; 7(11):1835-44. PubMed ID: 19843632 [Abstract] [Full Text] [Related]
4. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E. Apoptosis; 2007 Aug 18; 12(8):1533-41. PubMed ID: 17520194 [Abstract] [Full Text] [Related]
5. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. Choi SY, Kim MJ, Chung HY, Lee SJ, Jang YJ. Oncol Rep; 2007 Jan 18; 17(1):175-84. PubMed ID: 17143496 [Abstract] [Full Text] [Related]
6. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Cancer Res; 1999 Feb 01; 59(3):734-41. PubMed ID: 9973225 [Abstract] [Full Text] [Related]
7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373 [Abstract] [Full Text] [Related]
8. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC. Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300 [Abstract] [Full Text] [Related]
9. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Zhang Y, Zhang B. Mol Cancer Res; 2008 Dec 01; 6(12):1861-71. PubMed ID: 19074831 [Abstract] [Full Text] [Related]
10. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH. Biochem Pharmacol; 2009 Apr 15; 77(8):1328-36. PubMed ID: 19426671 [Abstract] [Full Text] [Related]
11. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S. Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):543-52. PubMed ID: 18793956 [Abstract] [Full Text] [Related]
12. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886 [Abstract] [Full Text] [Related]
13. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents. Sun J, Fu ZM, Fang CQ, Li JH. Chin Med J (Engl); 2007 Mar 05; 120(5):400-4. PubMed ID: 17376311 [Abstract] [Full Text] [Related]
14. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression. Shi P, Wang MM, Jiang LY, Liu HT, Sun JZ. Chin Med J (Engl); 2008 Oct 20; 121(20):1975-9. PubMed ID: 19080259 [Abstract] [Full Text] [Related]
15. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cancer Res; 2005 Dec 15; 65(24):11447-58. PubMed ID: 16357153 [Abstract] [Full Text] [Related]
16. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR. Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135 [Abstract] [Full Text] [Related]
17. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726 [Abstract] [Full Text] [Related]
18. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Gynecol Oncol; 2001 Jun 01; 81(3):380-90. PubMed ID: 11371126 [Abstract] [Full Text] [Related]
19. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Lee AL, Dhillon SH, Wang Y, Pervaiz S, Fan W, Yang YY. Mol Biosyst; 2011 May 01; 7(5):1512-22. PubMed ID: 21350763 [Abstract] [Full Text] [Related]
20. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M. Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127 [Abstract] [Full Text] [Related] Page: [Next] [New Search]